Attached files

file filename
EX-14.1 - EX-14.1 - IONIS PHARMACEUTICALS INCa13-25938_1ex14d1.htm

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

 

FORM 8-K

 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported):  December 9, 2013

 

ISIS PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

(State or Other Jurisdiction of Incorporation)

 

000-19125

 

33-0336973

(Commission File No.)

 

(IRS Employer Identification No.)

 

2855 Gazelle Court

Carlsbad, CA 92010

(Address of Principal Executive Offices and Zip Code)

 

Registrant’s telephone number, including area code: (760) 931-9200

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o                 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o                 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o                 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o                 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.05                                           Amendments to the Registrant’s Code of Ethics.

 

On December 5, 2013, Isis Pharmaceuticals, Inc. amended its Code of Ethics and Business Conduct to add additional procedures for the pre-clearance of trades in Isis’ stock by employees who do not use Rule 10b5-1 plans.

 

A copy of the amended Code of Ethics and Business Conduct is included with this report as Exhibit 14.1 and incorporated herein by reference.

 

Item 9.01.                                        Financial Statements and Exhibits.

 

(d)  Exhibits.

 

14.1                                            Registrant’s Code of Ethics and Business Conduct. 

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

ISIS PHARMACEUTICALS, INC.

 

 

 

 

Dated: December 9, 2013

By:

/s/ B. Lynne Parshall

 

 

B. LYNNE PARSHALL

 

 

Chief Operating Officer

 

 

and Director

 

3



 

INDEX TO EXHIBITS

 

14.1                        Registrant’s Code of Ethics and Business Conduct.

 

4